EligibleTrials

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Recruiting · NCT07403669 · Interventional (participants receive a specific treatment) · Lead sponsor: Aventyn, Inc.

View the official record on ClinicalTrials.gov →
Chronic kidney diseaseHeart Failure

Interventions studied

CHAPERONE AICKMiq AIQuality of Life

What this trial is about

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

10 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.